Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.85 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.52 |
| ▸ | ATP4A | P20648 | 5/20 | 0.52 |
| ▸ | ATP4B | P51164 | 5/20 | 0.52 |
| ▸ | ATP1A1 | P05023 | 4/20 | 0.52 |
| ▸ | ATP1B1 | P05026 | 4/20 | 0.52 |
| ▸ | ATP1A3 | P13637 | 4/20 | 0.52 |
| ▸ | ATP1B2 | P14415 | 4/20 | 0.52 |
| ▸ | ATP1A2 | P50993 | 4/20 | 0.52 |
| ▸ | ATP1B3 | P54709 | 4/20 | 0.52 |
| ▸ | FXYD2 | P54710 | 4/20 | 0.52 |
| ▸ | ATP1A4 | Q13733 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | WDR5 | P61964 | 3/20 | 0.52 |
| ▸ | BRS3 | P32247 | 2/20 | 0.52 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.52 |
| ▸ | ENGASE | Q8NFI3 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Omeprazole Sulfone SCHEMBL33721996 | 1.00 | CYP2C9 (0.85) | CYP2C9KMT2AATP4AATP4BATP1A1 | |
| Omeprazole Sulfone SCHEMBL29415504 | 1.00 | CYP2C9 (0.85) | CYP2C9KMT2AATP4AATP4BATP1A1 | |
| Omeprazole Sulfone SCHEMBL28015857 | 0.99 | CYP2C9 (0.83) | CYP2C9KMT2AATP4AATP4BATP1A1 | |
| Omeprazole Sulfone SCHEMBL4950986 | 0.92 | CYP2C9 (1.00) | CYP2C9KMT2AATP4AATP4BATP1A1 | |
| SCHEMBL23988472 | 0.90 | CYP2C9 (0.70) | CYP2C9KMT2AATP4AATP4BATP1A1 | |
| SCHEMBL23988443 | 0.90 | CYP2C9 (0.70) | CYP2C9KMT2AATP4AATP4BATP1A1 | |
| SCHEMBL1477733 | 0.90 | CYP2C9 (0.69) | CYP2C9KMT2AATP4AATP4BATP1A1 | |
| SCHEMBL23988514 | 0.90 | CYP2C9 (0.69) | CYP2C9KMT2AATP4AATP4BATP1A1 | |
| SCHEMBL13645222 | 0.88 | CYP2C9 (0.67) | CYP2C9KMT2AATP4AATP4BATP1A1 | |
| SCHEMBL23988476 | 0.86 | CYP2C9 (0.76) | CYP2C9KMT2AATP4AATP4BATP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112255352-B | Method for detecting related substances of esomeprazole sodium for injection | 海南卫康制药(潜山)有限公司 | 2022-10-14 | — | — | CN | claimed |
| CN-111714639-A | Composition comprising histamine release-promoting substance and benzimidazole derivative | 黄泳华 | 2020-09-29 | — | — | CN | claimed |
| CN-111084886-A | Composition comprising fatty acid or derivative thereof and benzimidazole derivative | 黄泳华 | 2020-05-01 | — | — | CN | claimed |
| EP-2534144-B1 | Preparation process of the sodium salt of Esomeprazole | ESTEVE QUÍMICA S A (ES) | 2014-09-03 | — | — | EP | claimed |
| US-8680284-B2 | Preparation process of the sodium salt of esomeprazole | ESTEVE QUIMICA, S.A. (ES) | 2014-03-25 | — | — | US | claimed |
| EP-2534144-A1 | PREPARATION PROCESS OF THE SODIUM SALT OF ESOMEPRAZOLE | Esteve Química, S.A. (ES) | 2012-12-19 | — | — | EP | claimed |
| US-20120309976-A1 | PREPARATION PROCESS OF THE SODIUM SALT OF ESOMEPRAZOLE | Esteve Química, S.A. (ES) | 2012-12-06 | — | — | US | claimed |
| WO-2011098553-A1 | PREPARATION PROCESS OF THE SODIUM SALT OF ESOMEPRAZOLE | Esteve Química, S.A. (ES) | 2011-08-18 | — | — | WO | claimed |
| EP-1240159-A4 | IMPROVED OMEPRAZOLE PROCESS AND COMPOSITIONS THEREOF | ASTRAZENECA AB (SE) | 2003-04-16 | — | — | EP | claimed |
| EP-1240159-A1 | IMPROVED OMEPRAZOLE PROCESS AND COMPOSITIONS THEREOF | Merck & Co., Inc. (US) | 2002-09-18 | — | — | EP | claimed |
| WO-2001044231-A1 | IMPROVED OMEPRAZOLE PROCESS AND COMPOSITIONS THEREOF | MERCK & CO., INC. (US) | 2001-06-21 | — | — | WO | claimed |
| US-6191148-B1 | Purity; extremely low residual ethanol, less than 500 parts per million | MERCK & CO., INC. | 2001-02-20 | — | — | US | claimed |
| WO-2023175090-A1 | LIQUID PHARMACEUTICAL FORMULATION OF OMEPRAZOLE OR ESOMEPRAZOLE | ALKALOID AD SKOPJE (MK) | 2023-09-21 | — | — | WO | disclosed |
| CN-116036030-A | Omeprazole sodium freeze-dried powder injection for injection and preparation method thereof | 北京悦康科创医药科技股份有限公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-116041325-A | Method for stabilizing proton pump inhibitors | 山东北大高科华泰制药有限公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-115919851-A | Omeprazole sodium freeze-dried powder composition for injection and application thereof | 山东北大高科华泰制药有限公司 | 2023-04-07 | — | — | CN | disclosed |
| US-6229021-B1 | Method of omeprazole preparation | SLOVAKOFARMA, A.S. (SK) | 2001-05-08 | — | — | US | disclosed |
| US-6191148-B1 | Purity; extremely low residual ethanol, less than 500 parts per million | MERCK & CO., INC. | 2001-02-20 | — | — | US | disclosed |
| EP-0931076-A1 | METHOD OF OMEPRAZOLE PREPARATION | Slovakofarma, A.S. (SK) | 1999-07-28 | — | — | EP | disclosed |
| WO-1998009962-A1 | METHOD OF OMEPRAZOLE PREPARATION | SLOVAKOFARMA, A.S. (SK) | 1998-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309976-A1 | PREPARATION PROCESS OF THE SODIUM SALT OF ESOMEPRAZOLE | CYP2E1, ADH1C, ADH1A | CYP2C9 39/4885KMT2A 3529/4885ATP4A 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.